Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer
暂无分享,去创建一个
H. Urlaub | T. Lange | M. Jücker | H. Bohnenberger | T. Oellerich | S. Küffer | B. Danner | V. Labitzky | Sha Yao | P. Ströbel | O. Elakad | Björn Häupl | A. von Hammerstein-Equord | Stefan Küffer
[1] Yongheng Chen,et al. FGFR-TKI resistance in cancer: current status and perspectives , 2021, Journal of Hematology & Oncology.
[2] H. Bohnenberger,et al. Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer , 2020, Cancer medicine.
[3] Z. Qiu,et al. Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. , 2020, Oncology letters.
[4] R. Laskawi,et al. Shallow whole genome sequencing of adenoid cystic carcinomas of the salivary glands identifies specific chromosomal aberrations related to tumor progression. , 2020, Oral oncology.
[5] J. Luo,et al. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Neil Vasan,et al. A view on drug resistance in cancer , 2019, Nature.
[7] R. Herbst,et al. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) , 2019, Journal of Thoracic Oncology.
[8] J. Molina,et al. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. , 2019, Mayo Clinic proceedings.
[9] K. Tamura,et al. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Martin Eisenacher,et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..
[11] M. Katoh. Fibroblast growth factor receptors as treatment targets in clinical oncology , 2018, Nature Reviews Clinical Oncology.
[12] Yang Shen,et al. Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. , 2018, Cancer discovery.
[13] Kerstin Kutsche,et al. Activating Mutations in PAK1, Encoding p21-Activated Kinase 1, Cause a Neurodevelopmental Disorder. , 2018, American journal of human genetics.
[14] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[15] T. Beißbarth,et al. Comparative proteomics reveals a diagnostic signature for pulmonary head‐and‐neck cancer metastasis , 2018, EMBO molecular medicine.
[16] S. Moran,et al. Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells , 2018, Oncotarget.
[17] C. Chen,et al. The biology and role of CD44 in cancer progression: therapeutic implications , 2018, Journal of Hematology & Oncology.
[18] Yidan Ren,et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance , 2018, Molecular Cancer.
[19] N. Xu,et al. ANXA1 affects cell proliferation, invasion and epithelial-mesenchymal transition of oral squamous cell carcinoma. , 2017, Experimental and therapeutic medicine.
[20] S. Yano,et al. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer , 2017, Carcinogenesis.
[21] Zachary L. Skidmore,et al. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer , 2017, Clinical Cancer Research.
[22] H. Ditzel,et al. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer , 2017, Nature Communications.
[23] M. Berger,et al. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers , 2017, Clinical Cancer Research.
[24] Gabriela Alexe,et al. Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia , 2017, Cancer cell.
[25] N. Leighl,et al. Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine , 2017, Front. Oncol..
[26] J. Datta,et al. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398 , 2017, Molecular Cancer Therapeutics.
[27] Manuel Hidalgo,et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Hue Lee,et al. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness , 2016, Scientific Reports.
[29] Huiming Sun,et al. Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target , 2016, Tumor Biology.
[30] B. Cho,et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy , 2016, Oncogenesis.
[31] M. Mann,et al. A Proteomics Approach to the Protein Normalization Problem: Selection of Unvarying Proteins for MS-Based Proteomics and Western Blotting. , 2016, Journal of proteome research.
[32] G. Baldwin,et al. Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer , 2016, Cancer biology & therapy.
[33] M. Słabicki,et al. Elucidation of tonic and activated B-cell receptor signaling in Burkitt’s lymphoma provides insights into regulation of cell survival , 2016, Proceedings of the National Academy of Sciences.
[34] C. Arteaga,et al. Is There a Future for AKT Inhibitors in the Treatment of Cancer? , 2016, Clinical Cancer Research.
[35] M. Kodaira,et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.
[36] Jun Liu,et al. A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type , 2016, Oncology letters.
[37] G. Giaccone,et al. Refining the treatment of NSCLC according to histological and molecular subtypes , 2015, Nature Reviews Clinical Oncology.
[38] R. Herbst,et al. Lung Cancer in the Era of Precision Medicine , 2015, Clinical Cancer Research.
[39] A. Giuliano,et al. Critical protein GAPDH and its regulatory mechanisms in cancer cells , 2015, Cancer biology & medicine.
[40] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[41] H. Popper,et al. Molecular testing in lung cancer in the era of precision medicine. , 2014, Translational lung cancer research.
[42] A. Strasser,et al. Pro-apoptotic BIM is an essential initiator of physiological endothelial cell death independent of regulation by FOXO3 , 2014, Cell Death and Differentiation.
[43] A. Iafrate,et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] J. Wolf,et al. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer , 2014, Modern Pathology.
[45] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[46] M. Tenhagen,et al. p120-catenin in cancer – mechanisms, models and opportunities for intervention , 2013, Journal of Cell Science.
[47] Mari Mino-Kenudson,et al. FGFR1 Amplification in Squamous Cell Carcinoma of The Lung , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[48] T. Zander,et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer , 2012, Modern Pathology.
[49] S. MacGrath,et al. Cortactin in cell migration and cancer at a glance , 2012, Journal of Cell Science.
[50] D. Coppola,et al. Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice , 2011, Clinical Cancer Research.
[51] I. Petersen,et al. Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.
[52] A. Ashworth,et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.
[53] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[54] V. Shidham,et al. Cell Block Preparation from Cytology Specimen with Predominance of Individually Scattered Cells , 2009, Journal of visualized experiments : JoVE.
[55] M. Mann,et al. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.
[56] Viraj J. Jasinghe,et al. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion , 2008, Cancer Chemotherapy and Pharmacology.
[57] J. Testa,et al. Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.
[58] Xin Zhao,et al. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[59] G. Bokoch,et al. Akt Phosphorylation of Serine 21 on Pak1 Modulates Nck Binding and Cell Migration , 2003, Molecular and Cellular Biology.
[60] Liuh-Yow Chen,et al. Daxx Silencing Sensitizes Cells to Multiple Apoptotic Pathways , 2003, Molecular and Cellular Biology.
[61] D. Reinberg,et al. ASAP, a Novel Protein Complex Involved in RNA Processing and Apoptosis , 2003, Molecular and Cellular Biology.